Balance Sheet Insights: Procept BioRobotics Corp (PRCT)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Procept BioRobotics Corp (NASDAQ: PRCT) closed at $72.10 down -1.22% from its previous closing price of $72.99. In other words, the price has decreased by -$1.22 from its previous closing price. On the day, 0.65 million shares were traded. PRCT stock price reached its highest trading level at $73.96 during the session, while it also had its lowest trading level at $71.54.

Ratios:

For a deeper understanding of Procept BioRobotics Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.49 and its Current Ratio is at 7.51. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.31.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 11, 2023, initiated with a Overweight rating and assigned the stock a target price of $42.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 16 ’24 when Waters Kevin sold 25,000 shares for $82.51 per share. The transaction valued at 2,062,679 led to the insider holds 96,096 shares of the business.

Kevin Waters bought 50,000 shares of PRCT for $4,055,500 on Sep 16 ’24. On Sep 12 ’24, another insider, Desai Antal Rohit, who serves as the Director of the company, sold 44,867 shares for $80.11 each. As a result, the insider received 3,594,377 and left with 197,453 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRCT now has a Market Capitalization of 3744318720 and an Enterprise Value of 3613181184. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.20 while its Price-to-Book (P/B) ratio in mrq is 14.86. Its current Enterprise Value per Revenue stands at 20.463 whereas that against EBITDA is -34.471.

Stock Price History:

Over the past 52 weeks, PRCT has reached a high of $85.81, while it has fallen to a 52-week low of $24.83. The 50-Day Moving Average of the stock is -3.31%, while the 200-Day Moving Average is calculated to be 19.72%.

Shares Statistics:

For the past three months, PRCT has traded an average of 704.35K shares per day and 723540 over the past ten days. A total of 50.77M shares are outstanding, with a floating share count of 48.95M. Insiders hold about 5.74% of the company’s shares, while institutions hold 84.78% stake in the company. Shares short for PRCT as of 1727654400 were 5516627 with a Short Ratio of 7.83, compared to 1724976000 on 6019457. Therefore, it implies a Short% of Shares Outstanding of 5516627 and a Short% of Float of 14.580000000000002.

Most Popular